secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prime Medicine, Inc. (PRME)
CIK:        0001894562
Form:       8-K
Filed at:   2024-03-01T23:59:59+00:00
Accession:  0001628280-24-008113
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prime Medicine reports FY2023 net loss of $198.1M; eyes IND/CTA for CGD in 1H 2024
--------------------------------------------------------------------------------

- Net loss widened to $198.1M in FY2023 ($121.8M in FY2022); R&D expenses $147.9M up from $86.7M.
- Cash, equivalents, investments, restricted cash $135.2M at Dec 31, 2023, vs $307.4M year earlier.
- Closed upsized public offering in Feb 2024, gross proceeds ~$161.0M at $6.25 per share.
- Expects to file IND/CTA for PM359 (CGD) in 1H 2024; initial clinical data anticipated in 2025.
- Received Orphan Drug Designation for PM359; $15M CF Foundation funding for CF Prime Editors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1894562/000162828024008113/0001628280-24-008113-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1894562/000162828024008113/prme-20240301.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-008113

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer